Multiple anti-CD40L or anti-CD40 drugs have been developed to reduce the risk of thromboembolic complications, such as dapirolizumab pegol (CDP7657) and VIB4920 in lupus, diabetes, Sjogren disease, and other autoimmune diseases. Here, CD40LG is linked to systemic lupus erythematosus.